Bullous Sweet syndrome in a patient with acute myeloid leukemia treated with midostaurin: Rapid response to acitretin and colchicine—A case report

Chiewchanvit, Siri; Jamjanya, Sirinda; Rattanathammethee, Thanawat; Mahanupab, Pongsak; Tovanabutra, Napatra; Chuamanochan, Mati

doi:10.1111/dth.15171

Cited by 5 publications

(3 citation statements)

References 9 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent case reports have also demonstrated efficacy for baricitinib (a Janus kinase inhibitor) [141], thalidomide [128], and combination acitretin and colchicine therapy [161]. A number of biologic agents have also been recently reported as viable management options for refractory SS: adalimumab [162] and infliximab [23,37,163] (anti-tumor necrosis factor alpha [TNFα] agents), anakinra [164] and rilonacept [91] (anti-IL1 agents), and tocilizumab (anti-IL6) [146,150].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

New Practical Aspects of Sweet Syndrome

et al. 2022

View full text Add to dashboard Cite

Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is an inflammatory, non-infectious skin reaction characterized clinically by tender, erythematous papules/plaques/pustules/nodules commonly appearing on the upper limbs, trunk, and head and neck; histologically, SS is characterized by dense neutrophilic infiltrate in the dermis. SS is accompanied by fever; an elevation of inflammatory markers (e.g., erythrocyte sedimentation rate, C reactive protein) in serum may also be observed. Although most cases of SS are idiopathic, SS also occurs in the setting of malignancy or following administration of an associated drug. SS has also been reported in association with pregnancy and a burgeoning list of infectious (most commonly upper respiratory tract infections) and inflammatory diseases; likewise, the litany of possible iatrogenic triggers has also grown. Over the past several years, a wider spectrum of SS presentation has been realized, with several reports highlighting novel clinical and histological variants. Corticosteroids continue to be efficacious first-line therapy for the majority of patients with SS, although novel steroid-sparing agents have been recently added to the therapeutic armamentarium against refractory SS. New mechanisms of SS induction have also been recognized, although the precise etiology of SS still remains elusive. Here, we catalogue the various clinical and histological presentations of SS, summarize recently reported disease associations and iatrogenic triggers, and review treatment options. We also attempt to frame the findings of this review in the context of established and emerging paradigms of SS pathogenesis.

show abstract

Section: Therapeutic Optionsmentioning

confidence: 99%

New Practical Aspects of Sweet Syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Rash was reported as a side effect, but there are no reports of SS in clinical trials [22]. To the best of our knowledge, there are three case reports of patients who developed Sweet's syndrome while being treated with midostaurin [23][24][25]. Our patient developed SS just three days after starting the treatment.…”

Section: Discussionmentioning

confidence: 69%

A Rare Case of Midostaurin-Associated Sweet’s Syndrome

Yasin

Laytem

Sutamtewagul

et al. 2022

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…The use of colchicine 0.6 mg twice daily led to the resolution of SS but it had to be continued for almost 10 years to avoid new cutaneous relapses [79]. A Thai group reported the case of a patient affected by a bullous SS responding to a combination therapy of acitretin and colchicine [80]. Colchicine remains a mainstay in the management of SS in patients that are not responsive to systemic corticosteroids.…”

Section: Sweet Syndromementioning

confidence: 99%

Colchicine in Managing Skin Conditions: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

(1) Background: Colchicine is a natural alkaloid with anti-inflammatory properties used to treat various disorders, including some skin diseases. This paper aims to incorporate all the available studies proposing colchicine as a treatment alternative in the management of cutaneous conditions. (2) Methods: In this systematic review, the available articles present in various databases (PubMed, Scopus-Embase, and Web of Science), proposing colchicine as a treatment for cutaneous pathological conditions, have been selected. Exclusion criteria included a non-English language and non-human studies. (3) Results: Ninety-six studies were included. Most of them were case reports and case series studies describing colchicine as single therapy, or in combination with other drugs. Hidradenitis suppurativa, pyoderma gangrenosum, erythema nodosum, erythema induratum, storage diseases, perforating dermatosis, bullous diseases, psoriasis, vasculitis, acne, urticaria, stomatitis, actinic keratosis, and pustular dermatosis were the main diseases discussed in literature. Although the therapeutic outcomes were variable, most of the studies reported, on average, good clinical results (4) Conclusions: Colchicine could be, as a single therapy or in combination with other drugs, a possible treatment to manage several skin diseases.

show abstract

Bullous Sweet syndrome in a patient with acute myeloid leukemia treated with midostaurin: Rapid response to acitretin and colchicine—A case report

Cited by 5 publications

References 9 publications

New Practical Aspects of Sweet Syndrome

New Practical Aspects of Sweet Syndrome

A Rare Case of Midostaurin-Associated Sweet’s Syndrome

Colchicine in Managing Skin Conditions: A Systematic Review

Contact Info

Product

Resources

About